Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771359 | 0.91 | PIK3CD (0.51) | PIK3CDMAPK10PIK3R1GRM5PIK3CA | |
| SCHEMBL2056476 | 0.82 | PIK3CD (0.58) | PIK3CDMAPK10PIK3CAPIK3CBPIK3CG | |
| SCHEMBL1779296 | 0.76 | GRM5 (0.46) | GRM5IRAK4P2RX7 | |
| SCHEMBL1771747 | 0.76 | PIK3CD (0.56) | PIK3CDMAPK10PIK3R1PIK3CAPIK3C3 | |
| SCHEMBL1779880 | 0.74 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3C3PIK3CBPIK3CG | |
| SCHEMBL2056081 | 0.74 | PIK3CD (0.70) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL1779380 | 0.74 | PIK3CD (0.53) | PIK3CDGRM5PIK3CAIRAK4PIK3CB | |
| SCHEMBL1772279 | 0.73 | PIK3CD (0.63) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL1118919 | 0.72 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL1252861 | 0.72 | L3MBTL1 (0.38) | PIK3CDPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | CDK3, CDK13, MAP3K13 | PIK3CD 111/4885MAPK10 410/4885PIK3R1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.